Ethical challenges are central to persistent "critical weaknesses" in the national system for ensuring drug safety, according to a commentary by former Institute of Medicine (IOM) committee members published today in the New England Journal of Medicine.
URL: http://www.disabled-world.com/medical/pharmaceutical/fda/postmarket.php
No comments:
Post a Comment